OncoMatch/Clinical Trials/NCT07222267
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Is NCT07222267 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BG-75202 and CDK4 Inhibitor for breast cancer.
Treatment: BG-75202 · CDK4 Inhibitor · Estrogen Receptor Antagonist · Aromatase Inhibitor — The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-75202 (KAT6A/B inhibitor) alone and in combination with other therapies in participants with breast cancer and other advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: KAT6A/B or KAT7 inhibitor/degrader
Prior exposure to KAT6A/B or KAT7 inhibitors/degraders
Lab requirements
Blood counts
Kidney function
Liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University in St Louis · St Louis, Missouri
- Next Oncology Austin · Austin, Texas
- The University of Texas Md Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify